Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study

dc.creatorBatista, Jose Gomes
dc.creatorSoares-Jr, Jose Maria
dc.creatorMaganhin, Carla Cristina
dc.creatorSimões, Ricardo dos Santos
dc.creatorTomaz, Geraldez
dc.creatorBaracat, Edmund Chada
dc.date.accessioned2013-11-01T10:36:22Z
dc.date.accessioned2018-07-04T16:08:28Z
dc.date.available2013-11-01T10:36:22Z
dc.date.available2018-07-04T16:08:28Z
dc.date.created2013-11-01T10:36:22Z
dc.date.issued2012
dc.identifierCLINICS, SAO PAULO, v. 67, n. 3, pp. 283-287, AUG, 2012
dc.identifier1807-5932
dc.identifierhttp://www.producao.usp.br/handle/BDPI/37244
dc.identifier10.6061/clinics/2012(03)14
dc.identifierhttp://dx.doi.org/10.6061/clinics/2012(03)14
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1631956
dc.languageeng
dc.publisherHOSPITAL CLINICAS, UNIV SAO PAULO
dc.publisherSAO PAULO
dc.relationCLINICS
dc.rightsCopyright HOSPITAL CLINICAS, UNIV SAO PAULO
dc.rightsopenAccess
dc.titleAssessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución